Cargando…

Definitions of “Cure” After Low-Dose-Rate Brachytherapy in Low- and Intermediate-Risk Prostate Cancer: Phoenix or Surgical?

PURPOSE: The aim of this study was to compare a surgical with a Phoenix-derived definition of cure at 4 years after treatment by (125)J low-dose-rate brachytherapy (LDR-BT) in patients with low- and intermediate-risk prostate cancer. METHODS AND MATERIALS: A total of 427 evaluable men with low-risk...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boehle, Andreas, Zywietz, Dorothea, Robrahn-Nitschke, Irina, Koenig, Inke R., Lusch, Achim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Scientific Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9943771/ https://www.ncbi.nlm.nih.gov/pubmed/36845613 http://dx.doi.org/10.1016/j.adro.2022.101112

Ejemplares similares

Low‐Dose‐Rate Prostate Brachytherapy (LDR‐PB) adopts postsurgical PSA value for definition of cure
por: Uribe, Jennifer, et al.
Publicado: (2020)

Focal low-dose-rate prostate brachytherapy for low- and intermediate-risk prostate cancer
por: Kunogi, Hiroaki, et al.
Publicado: (2020)

Re: Results of a randomized trial of treatment modalities in patients with low or early‑intermediate risk prostate cancer (PREFERE trial)
por: Boehle, Andreas, et al.
Publicado: (2021)

Focal low dose-rate brachytherapy for low to intermediate risk prostate cancer: preliminary experience at an Australian institution
por: Anderson, Elliot, et al.
Publicado: (2021)

Direct comparison of low-dose-rate brachytherapy versus radical prostatectomy using the surgical definition of biochemical recurrence for patients with intermediate-risk prostate cancer
por: Tsumura, Hideyasu, et al.
Publicado: (2022)

Clinical outcomes of low-dose-rate brachytherapy based radiotherapy for intermediate risk prostate cancer
por: Okamoto, Keisei, et al.
Publicado: (2020)

Low dose rate prostate brachytherapy
por: Stish, Bradley J., et al.
Publicado: (2018)

Direct Comparison of Two Different Definitions with Biochemical Recurrence after Low-Dose-Rate Brachytherapy for Prostate Cancer
por: Takeuchi, Shinichi, et al.
Publicado: (2023)

After low and high dose-rate interstitial brachytherapy followed by IMRT radiotherapy for intermediate and high risk prostate cancer
por: Nakamura, Satoshi, et al.
Publicado: (2016)

Do androgen deprivation and the biologically equivalent dose matter in low‐dose‐rate brachytherapy for intermediate‐risk prostate cancer?
por: Tabata, Ryuji, et al.
Publicado: (2016)

Utilization of prostate brachytherapy for low risk prostate cancer: Is the decline overstated?
por: Safdieh, Joseph, et al.
Publicado: (2016)

High-dose-rate brachytherapy as monotherapy for low- and intermediate-risk prostate cancer: long-term experience of Swedish single-center
por: Johansson, Bengt, et al.
Publicado: (2021)

Long-term results with custom-linked iodine-125 seeds and real-time brachytherapy in low- and intermediate-risk prostate cancer
por: Guinot, Jose Luis, et al.
Publicado: (2022)

Comparative effectiveness of low-dose-rate brachytherapy with or without external beam radiotherapy in favorable and unfavorable intermediate-risk prostate cancer
por: Tsumura, Hideyasu, et al.
Publicado: (2022)

The biochemical recurrence-free rate in patients who underwent prostate low-dose-rate brachytherapy, using two different definitions
por: Tanaka, Nobumichi, et al.
Publicado: (2014)

Determining Combined Modality Dosimetric Constraints by Integration of IMRT and LDR Prostate Brachytherapy Dosimetry and Correlation with Toxicity
por: Riegel, Adam C., et al.
Publicado: (2022)

Factors Affecting Prostate Displacement During Volumetric Modulated Arc Therapy in Prone Position After High-Dose-Rate Brachytherapy for Prostate Cancer
por: Sakurai, Takayuki, et al.
Publicado: (2023)

Salvage Prostate Stereotactic Body Radiation Therapy After Definitive Cryoablation
por: Lischalk, Jonathan W., et al.
Publicado: (2021)

Focal low-dose rate brachytherapy for the treatment of prostate cancer
por: Tong, William Y, et al.
Publicado: (2013)

Excessive waitlists and delays to treatment with low-dose-rate brachytherapy predict an increased risk of recurrence and metastases in intermediate-risk prostatic carcinoma
por: Khanolkar, Rutvij A., et al.
Publicado: (2021)

Outpatient ocular brachytherapy: The USC Experience
por: Joh, Sarah, et al.
Publicado: (2021)

The relationship between the biochemical control outcomes and the quality of planning of high-dose rate brachytherapy as a boost to external beam radiotherapy for locally and locally advanced prostate cancer using the RTOG-ASTRO Phoenix definition
por: Pellizzon, Antonio Cassio Assis, et al.
Publicado: (2008)

Disparities in staging prostate magnetic resonance imaging utilization for nonmetastatic prostate cancer patients undergoing definitive radiation therapy
por: Ajayi, Ayobami, et al.
Publicado: (2016)

A novel perineal shield for low-dose-rate prostate brachytherapy
por: Weiner, Joseph P., et al.
Publicado: (2015)

The direct prognosis comparison of (125)I low-dose-rate brachytherapy versus laparoscopic radical prostatectomy for patients with intermediate-risk prostate cancer
por: Liang, Zhen, et al.
Publicado: (2023)

Phoenix
por: Cvetaeva, Marina
Publicado: (2001)

Definitive Radiation Treatment Patterns and Outcomes for Low and Intermediate Risk Prostate Cancer Patients: A Cross-Continental Comparative Study
por: Asamoah, Francis A., et al.
Publicado: (2019)

Being certain about uncertainties: a robust evaluation method for high-dose-rate prostate brachytherapy treatment plans including the combination of uncertainties
por: Kennedy, Andrew C., et al.
Publicado: (2023)

Intracoronary brachytherapy for in-stent restenosis of drug-eluting stents
por: Ohri, Nisha, et al.
Publicado: (2015)

Focal partial salvage low-dose-rate brachytherapy for local recurrent prostate cancer after permanent prostate brachytherapy with a review of the literature
por: Kunogi, Hiroaki, et al.
Publicado: (2016)

MRI for managing intermediate & low risk prostate cancer
por: Padhani, Anwar R
Publicado: (2014)

High-Dose-Rate Brachytherapy as Monotherapy for Low- and Intermediate-Risk Prostate Cancer. Oncological Outcomes After a Median 15-Year Follow-Up
por: Behmueller, Manuel, et al.
Publicado: (2021)

Prostate-Centric Versus Bony-Centric Registration in the Definitive Treatment of Node-Positive Prostate Cancer with Simultaneous Integrated Boost: A Dosimetric Comparison
por: Wu, Trudy C., et al.
Publicado: (2022)

Trends in Androgen Deprivation Use in Men With Intermediate-Risk Prostate Cancer Who Underwent Radiation Therapy
por: Agrawal, Vishesh, et al.
Publicado: (2022)

PROSTATE-SPECIFIC ANTIGEN (PSA) VALUES IN PATIENTS WITH LOW- AND HIGH-RISK PROSTATIC ADENOCARCINOMA
por: Mašić, Silvija, et al.
Publicado: (2019)

A Phase 2 Randomized Pilot Study Comparing High-Dose-Rate Brachytherapy and Low-Dose-Rate Brachytherapy as Monotherapy in Localized Prostate Cancer
por: Hathout, Lara, et al.
Publicado: (2019)

Pulmonary Metastases After Low-Dose-Rate Brachytherapy for Localized Prostate Cancer
por: Kido, Masahito, et al.
Publicado: (2014)

A comparison study on various low energy sources in interstitial prostate brachytherapy
por: Bakhshabadi, Mahdi, et al.
Publicado: (2016)

Control charts for evaluation of quality of low-dose-rate brachytherapy for prostate cancer
por: Nasser, Nicola J., et al.
Publicado: (2022)

The oncologic and safety outcomes of low-dose-rate brachytherapy for the treatment of prostate cancer
por: Tanaka, Nobumichi
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_73icnkt24898blj510aff8u08q